By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Genmab A/S 

Toldbodgade 33

Copenhagen    K-1253  Denmark
Phone: 45-7020-2728 Fax: 45-7020-2729


Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX™ (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.


February 1999


CEO and Founder: Jan G. J. van de Winkel, Ph.D.

CFO: David Eatwell

Please click here for Genmab job opportunities.


Please click here for clinical trial information.


All Products


Key Statistics

Ownership: Public

Web Site: Genmab A/S
Symbol: GEN.CO



Bionomics Limited  Anti-angiogenesis therapeutic antibody development

Company News
Genmab A/S (GEN.CO) And Seattle Genetics (SGEN) To Co-Develop Tisotumab Vedotin For Solid Tumors 8/29/2017 6:25:04 AM
Genmab A/S (GEN.CO) Announces Positive Topline Results In Phase III ALCYONE Study Of Daratumumab In Front Line Multiple Myeloma 8/24/2017 8:18:35 AM
Capital Increase In Genmab A/S (GEN.CO) As A Result Of Employee Warrant Exercise 8/15/2017 10:19:18 AM
Genmab A/S (GEN.CO) Announces Net Sales Of DARZALEX (Daratumumab) For Second Quarter Of 2017 7/18/2017 10:52:36 AM
Grant Of Restricted Stock Units And Warrants To Genmab A/S (GEN.CO) Employees 6/9/2017 10:41:47 AM
Genmab A/S (GEN.CO) Announces Plans For New Studies Of Daratumumab 5/18/2017 11:15:34 AM
Capital Increase In Genmab A/S (GEN.CO) As A Result Of Employee Warrant Exercise 5/16/2017 10:30:28 AM
Genmab A/S (GEN.CO) Announces Financial Results For The First Quarter Of 2017 5/10/2017 12:32:38 PM
Genmab A/S (GEN.CO) Announces European Marketing Authorization For DARZALEX (Daratumumab) For Relapsed Or Refractory Multiple Myeloma 4/28/2017 8:09:53 AM
Genmab A/S (GEN.CO) Announces New Phase III Combination Study Of Daratumumab In Multiple Myeloma 4/28/2017 8:08:31 AM